IgE and Anti-IgE Therapy in Asthma and Allergic Disease

1. Introduction, 2. Serum IgE Distributions in Normal and Asthmatic Subjects, 3. Understanding the Binding of IgE to Its High-Affinity Receptor and to an Anti-IgE Antibody, 4. Mediator Release from Basophils and Mast Cells and Its Relationship to FcRI Expression and IgE-Suppressing Therapies, 5. Expression of IgE Receptors on Eosinophils, 6. Eosinophil IgE Receptors: Controversy and Consensus, 7. Murine Models of Asthma: Caveats and Conclusions on the Contribution of IgE and Mast Cells to Allergic Inflammation, Airway Hyperresponsiveness, and Airflow Obstruction, 8. Role of IgE in Asthma: Pathogenesis and Novel Therapeutic Strategies, 9. IgE-Mediated Response to Allergen in the Bronchoprovocation Laboratory, 10. Pathophysiology of the Airway Response to Inhaled Allergen in Asthmatic Subjects: Role of IgE, 11. Efficacy and Safety of Xolair Anti-IgE Monoclonal Antibody in Adult Asthmatics, 12. The Role of IgE in Pediatric Asthma, 13. Anti-inflammatory Activities of Omalizumab (Xolair), a Recombinant Humanized Monoclonal Antibody Binding IgE, 14. Pulmonary Delivery of Anti-IgE: Rationale for Topical Delivery to the Airway, 15. Treatment of Seasonal Allergic Rhinitis, 16. Anti-IgE and Allergic Skin Diseases, 17. Role of IgE and Food Allergens, 18. Role of IgE in Allergic Bronchopulmonary Aspergillosis, 19. IgE and Its Role in Parasitic Helminth Infection: Implications for Anti-IgE-Based Therapies, 20. The Rise of Antibodies as Therapeutics